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1. Introduction 
Accurate statistics on cancer occurrence and outcome are essential both for the purposes of 
research and for planning and evaluation programmes for cancer control (Parkin, 2006). 
Although tumours of thyroid account for only 1% of the overall human cancer burden, they 
represent the most common malignancies of the endocrine system and pose a significant 
challenge to pathologists, surgeons and endocrinologists. Among epithelial tumors, 
carcinomas of follicular cell origin far outnumber those of C-cell origin. The vast majority of 
carcinomas of follicular cell origin are indolent malignancies with 10 year survivals in excess 
of 90 %. 
1.1 Classification 
Thyroid follicular epithelial-derived cancers are divided into three categories: papillary 
cancer, follicular cancer and anaplastic cancer. Papillary and follicular cancers are 
considered differentiated cancers, and patients with these tumours are often treated 
similarly despite numerous biologic differences. Most anaplastic (undifferentiated) cancers 
appear to arise from differentiated cancers. Other malignant diseases of the thyroid include 
medullary thyroid cancer (which can be familial, either as part of the multiple endocrine 
neoplasia type 2 syndrome or isolated familial medullary thyroid cancer), primary thyroid 
lymphoma, or metastases from breast, colon, or renal cancer or melanoma. In countries with 
adequate iodine intake, differentiated thyroid cancer accounts for more than 85% of all 
cases, being the most common type papillary (60-80%). Tumor histology is a critical 
determinant of patient outcomes; differentiated thyroid cancer is associated with the best 
survival rate and medullary and anaplastic have significantly poorer outcomes (Hundahl et 
al., 1998). Certain subtypes, such as the tall and columnar cell variants of papillary cancer 
and the insular variant of follicular cancer are more common in older patients with higher 
stage disease and have a worse prognosis than usual forms of thyroid cancer. The 
traditional separation of thyroid cancer into the major groups of papillary, follicular, 
medullary and undifferentiated (anaplastic) carcinoma, based on morphology and clinical 
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features, is strongly supported by advances in molecular studies showing the involvement 
of distinct genes in these four groups, with little overlap (DeLellis & Williams, 2004). 
1.2 Staging and prognostic factors 
Numerous staging systems have been created in an attempt to accurately prognosticate 
outcomes for individual patients; two careful studies have compared the efficacy of the 
various staging systems and found that none is superior (Brierley et al., 1997; Sherman et al., 
1998). Consequently, the European Thyroid Association (ETA) (Pacini et al., 2006) and the 
American Thyroid Association (ATA) (Cooper et al., 2009)  have recommended the use of 
the Tumour, Node, Metastasis (TNM) classification of the American Joint Commission on 
Cancer (AJCC) and the International Union Against Cancer because it is universally 
available and widely accepted for other disease sites. An interesting feature of the TNM 
staging system compared to other classifications is the age factor. While the staging of head 
and neck cancers relies exclusively in the anatomical extent of disease, it is not possible to 
follow this pattern for the particular group of malignant tumors that arise in the thyroid 
gland. The effect of age is such significance in behavior and prognosis, that both the 
histologic diagnosis and the age of the patient are included in the staging system for these 
tumors. The AJCC classification is based on the TNM system, which relies on assessing three 
components: (1) extent of the primary tumour (T), (2) absence or presence of regional lymph 
node metastases (N), and (3) absence or presence of distant metastases (M). The fifth edition 
(Fleming et al., 1997), (Table 1) was revised as the sixth edition (Greene et al., 2002), (Table 2). 
A major alteration was the reclassification of tumour staging (T). For differentiated 
(papillary and follicular) and medullary tumours confined to the parenchyma of the thyroid 
gland without  extrathyroidal extension, there is no evidence to suggest that using a size cut-
off of 1 cm provides better prognostic stratification compared with the 2-cm cut-off used for  
 Papillary or Follicular Medullary Anaplastic 
Stage Age < 45 years Age > 45 years Any age 
I 
Any T Any N 
M0 
T1 N0 M0 T1 N0 M0 
 
II 
Any T Any N 
M1 
T2 N0 M0 
T3 N0 M0 
T2 N0 M0 
T3 N0 M0 
T4 N0 M0 
III 
 
T4 N0 M0 
Any T N1 M0 
Any T N1 M0 
 
 
IV 
Any T Any N 
M1 
Any T Any N M0
Any T Any N  
Any  M 
Table 1. AJCC TNM classification for thyroid cancer (fifth edition). T1 - Tumor 1 cm or less 
in greatest dimension limited to the thyroid. T2 - Tumour more than 1 cm, but not more 
than 4 cm, in greatest dimension limited to the thyroid. T3 - Tumour more than 4 cm in 
greatest dimension limited to the thyroid. T4 - Tumour of any size extending beyond the 
thyroid capsule. T4a - Excluded. T4b - Excluded. Regional lymph nodes are the cervical and 
upper mediastinal lymph nodes. N1a - Metastasis in ipsilateral cervical lymph node(s).  
N1b - Metastasis in bilateral, midline, or contralateral cervical or mediastinal lymph node 
(s). M0- no distance metastases; M1- distance metastases. 
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other head and neck sites. Therefore, fifth edition T1 (<1 cm) and T2 (between 1 and 4 cm) 
were redefined as sixth edition T1 (<2 cm) and T2 (between 2 and 4 cm). In the sixth edition, 
T3 includes not only large tumours (4 cm or more) but also tumours with minimal extension, 
and T4 consists of T4a and T4b. The fact that diverse outcomes may be expected in these two 
groups of patients is now recognized in the sixth edition: tumors that involve the 
sternothyroid muscle are classified as T3, while extension to larynx, trachea, oesophagus, 
recurrent laryngeal nerve, or subcutaneous soft tissue, all of which are surgically resectable, 
is classified as T4a. Tumours that invade the prevertebral fascia or encase the carotid artery 
or mediastinal great vessels are not resectable for cure, and these patients are staged T4b. 
Thus, the sixth edition divides fifth edition T4 tumors into T3 (minimal invasion), T4a 
(extended invasion), and T4b (more extensive unresectable invasion) tumours according to 
the degree of extrathyroid extension. The degree of extension has been closely related to 
adverse prognoses. Therefore, the sixth edition is expected to predict more accurately 
different outcomes in patients with extrathyroid extension compared with the fifth edition. 
 Papillary or Follicular Medullary Anaplastic 
Stage Age < 45 years Age > 45 years Any age
I 
Any T, Any N, 
M0
T1 N0 M0 T1 N0 M0 
 
II 
Any T Any N 
M1 
T2 N0 M0 T2 N0 M0 
III 
 
T3 N0 M0
T1 N1a M0 
T2 N1a M0 
T3 N1a M0 
T3 N0 M0
T1 N1a M0 
T2 N1a M0 
T3 N1a M0 
IVA 
T4a N0 M0
T4a N1a M0 
T1 N1b M0 
T2 N1b M0 
T3 N1b M0 
T4a N1b M0
T4a N0 M0
T4a N1a M0 
T1 N1b M0 
T2 N1b M0 
T3 N1b M0 
T4a N1b M0
T4a Any N M0 
IVB T4b Any N M0 T4b Any N M0 T4b Any N M0 
IVC 
Any T Any N 
M1 
Any T Any N M1 Any T Any N M1 
Table 2. AJCC TNM classification for thyroid cancer (sixth edition). T1 - Tumor 2 cm or less 
in greatest dimension limited to the thyroid. T2 - Tumour more than 2 cm, but not more 
than 4 cm, in greatest dimension limited to the thyroid. T3 - Tumour more than 4 cm in 
greatest dimension limited to the thyroid or any tumour with minimal extrathyroid 
extension (extension to sternothyroid muscle or perithyroid soft tissues). T4 - Excluded.  
T4a - Tumour of any size extending beyond the thyroid capsule to invade subcutaneous soft 
tissues, larynx, trachea, oesophagus, or recurrent laryngeal nerve. T4b - Tumour invades 
prevertebral fascia or encases carotid artery or mediastinal vessels. T4a - Intrathyroidal 
anaplastic carcinoma—surgically resectable. T4b - Extrathyroidal anaplastic carcinoma—
surgically unresectable. Regional lymph nodes are the central compartment, lateral cervical, 
and upper mediastinal lymph nodes. N1a - Metastasis to Level IV (pretracheal, paratracheal, 
and prelaryngeal/Delphian lymph nodes). N1b - Metastasis to unilateral, bilateral, or 
contralateral cervical or superior mediastinal lymph nodes. M0- no distance metastases;  
M1- distance metastases.  
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TNM classification is also used for hospital cancer registries and epidemiologic studies.  One 
of the greatest inadequacies of TNM system is that it is a static representation of the patient’s 
disease at the time of presentation; it does not allow for modification of risk during lifelong 
follow-up. Most patients with papillary cancer in the TNM system are classified as stage I 
disease (Hundahl et al., 1998), with an associated mortality rate of 1.7% (Loh et al., 1997). It 
is important to note, however, that there is a 15% recurrence rate 10 years after initial 
treatment (Loh et al., 1997). Recurrent or persistent disease, therefore, may necessitate 
additional therapy and can certainly affect the patient’s quality of life. Further limitations of 
tumour staging include the lack of consideration of tumour histology, extracapsular 
extension of the tumour or molecular characteristics of the primary tumour. As is well 
known, these factors can predict poorer outcomes for individual patients. As TNM staging 
was developed to predict risk of death and not recurrence, the ATA (Cooper et al., 2009) has 
created a more functional definition of risk stratification for individual patients that is 
similar to one outlined by the ETA ( Pacini et al., 2006). Patients are classified as low-risk if 
they have the following characteristics: no local or distant metastases, resection of all 
macroscopic tumour, no tumour invasion into locoregional tissues, tumour that is not an 
aggressive histological variant, no vascular invasion, and no uptake outside the thyroid bed 
on the post-treatment whole body scan (if 131I is given). Intermediate-risk patients are those 
with any of the following criteria: microscopic tumour invasion into the perithyroidal 
tissues at initial surgery, cervical lymph node metastases or 131I uptake outside the thyroid 
bed on the initial post-treatment scan, or tumour with aggressive histology or vascular 
invasion. Finally, high-risk patients have macroscopic tumour invasion, incomplete tumour 
resection, distant metastases or elevated thyroglobulin out of proportion to what is seen on 
the post-treatment scan (Cooper et al., 2009). This stratification was designed to help 
identify patients who are at higher risk for recurrent disease and may benefit from more 
aggressive postoperative management (Cooper et al., 2009). Such a definition of risk is more 
intuitive for the management of patients with thyroid cancer and is more in accordance with 
the clinical behaviour of these tumours.  
1.3 Epidemiology  
Epidemiology has shown the influence of factors such as age and sex on thyroid cancer 
incidence. Thyroid cancer is rare in children below 16 years, with an annual incidence 
between 0.02 and 0.3 cases per 100,000 children and occurs exceptionally before age 10. In 
adults, the mean age of diagnosis is the mid 40´s to early 50´s for the papillary type, 50´s for 
the follicular and medullary types and 60´s for the less common undifferentiated types. It is 
well established that thyroid cancer is 2 to 4 times more common in women than in men, 
although this will differ among countries. Nevertheless, this sex difference is far less 
pronounced before puberty and after menopause. Several epidemiological studies have 
examined several reproductive traits, but the cause of this increased prevalence of thyroid 
cancer in women is unclear. The annual incidence of thyroid cancer varies considerably in 
different registries, with the highest incidence rates in the world reported in Hawaii and 
Iceland (Ferlay et al., 2007; Kolonel et al., 1990). In Europe, the highest incidence occurs in 
Iceland, followed by Finland, while relatively low incidence characterizes the United 
Kingdom and Denmark (Ferlay et al., 2007,). These differences have been attributed to 
ethnic or environmental factors, but different standards of health care may also play a role 
in the efficiency of cancer detection. Although thyroid cancer incidence is low in general 
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when compared with other diseases and tumours, over the last few decades, increasing rates 
have been reported in several countries, including Europe (Akslen et al., 1993;  Colonna et 
al., 2002 ; dos Santos Silva et al., 1993; Gomez-Segovia et al., 2004; Petterson et al., 1991; 
Reynolds et al., 2005; Szybinski et al., 2003), the United States (Davies & Welch, 2006; Merhy 
et al., 2001; Zheng et al., 1996), Canada (Liu et al., 2001), and Australia (Burgess, 2002). 
Curiously, this increase has occurred almost exclusively in papillary thyroid cancer, with an 
epidemic of micropapillary thyroid carcinoma (MPTC) representing up to 43% of operated 
cancers in the present series (Leenhart et al., 2004a). The reasons for the rise in thyroid 
cancer incidence are not completely understood and considerable controversy exists now 
about whether this increase is real or only apparent due to an increase in diagnostic activity 
(Leenhart et al., 2004a; Leenhart et al., 2004b; Colonna et al., 2007). Recently, some 
researchers (Colonna et al., 2007; Davies & Welch, 2006; Kent et al., 2007) have suggested 
that this increase is predominantly due to the increased detection of small, subclinical 
tumours through the use of medical imaging. Moreover, thyroid surgery is constantly 
increasing, with more systematic use of total thyroidectomies even for benign pathologies, 
which makes it easier to detect MPTC. According to the World Health Organization (WHO), 
the term MPTC is used for a papillary carcinoma of the thyroid no larger than 1 cm in 
diameter (Hedinger et al., 1988). With the new classification published in 2004, the previous 
definition of MPTC now includes the additional criteria of being found incidentally (LiVolsi, 
2004). MPTC seems to be present in a significant proportion of the general population with 
large variations in the prevalence rate between different geographic areas (6–35%) (Sampson 
et al., 1974), which may also be due to differences in the depth of the pathological 
examination (Martinez-Tello et al., 1993). Although the mortality risk for an individual 
patient with thyroid cancer is the greatest concern for patients and clinicians alike, most 
patients have excellent 10-20-year disease specific survival (Hundahl et al., 1998). 
EUROCARE (European Cancer Registry-based Study on Survival and Care of Cancer 
Patients) is a collaborative project between European cancer registries (Capocaccia et al., 
2003). A major aim of EUROCARE is to estimate and compare cancer survival in European 
populations. EUROCARE-2 (Teppo & Hakulinen, 1998) was the first publication on thyroid 
cancer survival in Europe. This study included all malignant thyroid tumors (excluding 
lymphomas) in patients 15 or older. Relative survival was analyzed using population-based 
EUROCARE -2 data from 1985-1989. The overall 5-year relative survival rate, standardized 
by age (Table 3), was 67% for men and 78% for women across Europe. Substantial variation 
in this 5-year rate was observed between countries ranging from 56% in Slovenia to 100% in 
Austria (men), (Teppo & Hakulinen, 1998). Higher than average survival rates were 
observed in Finland, Iceland, The Netherlands and Sweden. Relative survival was higher in 
the younger population group. In the age group 15 - 44 years, for men the rate was at least 
86% and for women at least 94 %. In contrast, much lower rates were seen in the the group 
of older population (75 + years). EUROCARE-3 study (Sant et al., 2003) analyzed the 
survival of adult cancer diagnosed from 1990 to 1994 in 22 European countries and followed 
them until the end of 1998. Neoplasms in situ were collected but not included in the analysis 
of survival. The overall relative survival of patients diagnosed with thyroid cancer in this 
period was 83% at 5 years. Austria, Finland, France, Iceland, Italy, Norway, Malta, Spain, 
Switzerland and Sweden had rates above the European average. Most of these countries also 
had high survival for this cancer in EUROCARE-2. Denmark, Germany, The Netherlands, 
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England, Scotland, Wales and the countries of Eastern Europe had survival below the 
European average (Table 3). Again, the most favorable outcomes were observed in patients 
aged 15-44 years; for the oldest patient’s survival was five times lower. Part of variation in 
thyroid cancer survival was attributed to variations in the distribution of histological types. 
Other likely factors contributing to this are differences in the stage distribution and varying 
efficacy of treatment (Sant et al., 2003; Teppo & Hakulinen, 1998).  
 
 EUROCARE-2 EUROCARE-3 
 female male female male
Iceland 90 88 85 87,4 
Austria 87 100 88 81 
Sweden 84 74 85 80 
The Netherlands 84 77 79 68,6 
Finland 82 77 86 79 
France 81 61 85 74 
Switzerland 78 - 90 - 
Spain 78 70,6 85,7 82 
Italy 77 66 85 72,6 
Germany 77 62 77 69,4 
Estonia 76 57 77 58 
England 74 64 79 71 
Scotland 73 67 76 73 
Denmark 72 63 80 76,6 
Slovakia 71 63 76 - 
Eslovenia 70 56 77 83 
Poland 66 64 66 57 
EUROPE 78 67 81,4 71,8 
Table 3. Thyroid cancer 5-year Relative Survival (%) from 1985 to 1989 (EUROCARE-2) and 
from 1990 to 1994 (EUROCARE-3) in European countries.  
In the U.S., the National Cancer Data Base (NCDB) represents a national electronic registry 
system of incident cancers. Between 1985 and 1995, NCDB captured demographic, patterns-
of-care, stage, treatment, and outcome information for a sample of 53,856 thyroid carcinoma 
cases. The 10-year overall relative survival rates for U. S. patients with papillary, follicular, 
Hürthle cell, medullary, and undifferentiated/anaplastic carcinoma was 93%, 85%, 76%, 
75%, and 14%, respectively (Hundahl et al., 1998). Relative survival, the survival analogue of 
excess mortality, is commonly used in population-based studies of cancer survival although 
its utility is not restricted to this area. Relative survival is the ratio of the observed survival 
in a group of patients to the survival probability estimated over the same period in a group 
of people in the general population of similar age and sex. It is usual to estimate the 
expected survival proportion from nationwide population life tables stratified by age, sex, 
calendar time, and, where applicable, race (Berkson & Gage, 1950). In order to be 
comparable between different populations, relative survival figures must be either age-
specific or age-adjusted. A major advantage of relative survival is that information on cause 
of death is not required, thereby circumventing problems with the inaccuracy or no 
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availability of death certificates (Percy et al., 1981). However, our interest is typically in net 
survival rather than all-cause survival, that is, we are interested in mortality due to cancer. 
Cause-specific survival is commonly estimated in cancer clinical trials and only those deaths 
which can be attributed to the cancer in question are considered to be events, while all other 
deaths are considered censorings. Using cause-specific survival to estimate net survival 
requires that reliably coded information on cause of death is available. The distinguishing 
feature of survival analysis is that at the end of the follow-up period the event (such as 
death due to cancer) will probably not have occurred for all patients. For these patients the 
survival time is said to be censored, indicating that the observation period was cut off before 
the event occurred.  For example, a person who had the cancer and died 10 years later of car 
accident would be censored at death, having contributed 10 person-year of survival to the 
analysis. A person who had the cancer and died 10 years later of the cancer would 
contribute an event, a death due to the cancer, having also contributed 10 person-years of 
survival time. A 90 % cancer specific survival at 10 years would mean that 90 % of patients 
had not died from their cancer, while 10 % had died from their cancer (Kaplan, 1958). 
Calculation of cause-specific survival is especially important when studying diseases with a 
favorable prognosis, as is the case at hand, where the patients live long enough to be 
exposed to other causes of death. The indolent course of thyroid cancer requires very large 
cohorts of patients followed over several decades to confirm significant differences in 
prognostic factors and treatment efficacy. Neither randomized clinical trials nor meta-
analysis are available and evidence is based on a number of retrospective studies with 
multivariate for mortality risk factors or data from national cancer registries (Gilliland et al., 
1997; Hundahl et al., 1998). Unfortunately, very remarkable differences in patient’s selection, 
staging systems, and clinical management affect the available studies. In particular, 
radioiodine treatment is not routinely carried out in a standard manner and outcome results 
of different studies are thus not comparable (Sciuto et al., 2009).  Since scarce data exist on 
the epidemiology of thyroid cancer in Spain, the main aim of this study was to analyze 
changes in thyroid cancer presentation, incidence, prevalence and survival in South Galicia 
(north-western Spain) over a 24-year period (1978–2001) and compare these results with 
those described in the leading international series. The people of this region are 
homogeneous in terms of ethnicity. This period spans the population’s transition from mild 
iodine deficiency to iodine sufficiency after beginning iodine prophylaxis in 1985 (Garcia-
Mayor et al., 1999; Rego-Iraeta et al., 2007). As a high incidence of thyroid cancer owing to 
improved screening procedures is generally associated with an elevated proportion of small 
carcinomas, we have specifically considered the impact of MPTC on thyroid cancer 
incidence and trends in tumour size over time as an indicator of enhanced medical 
procedures for thyroid cancer. We have also studied the proportion of our population 
undergoing thyroid surgery over the study period and the percentage of thyroid cancers 
found per thyroidectomy performed. 
2. Materials and methods 
2.1 Identification of thyroid cancer cases 
Data on thyroid cancer incidence in the period from 1978 to 2001 (inclusive) were obtained 
from the Pathology Registry of the University Hospital of Vigo which belongs to the Spanish 
public health system and collects data on about 97% of the cancerous lesions verified by 
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microscopic examination. This ensures virtually complete ascertainment for all the new 
cases of thyroid cancer diagnosed in our population during the study period. Over the 
observation period, a total of 329 cases of thyroid cancer were registered. Seven cases (six 
lymphomas and one Angiosarcoma) were excluded from the study based on rarity. The 
remaining 322 cases of primary thyroid cancer were assigned to one of the four major 
diagnostic categories: papillary thyroid carcinoma; follicular thyroid carcinoma, including 
Hürthle carcinomas; medullary thyroid carcinoma; and anaplastic thyroid carcinoma, 
diagnosed according to the WHO classification (Hedinger et al., 1988). Original histology 
slides for all cases of follicular carcinomas (53 cases) were reviewed by two 
hystopathologists blinded to the original diagnosis. Nine of them were reclassified as 
papillary carcinomas and 44 cases were classified as true follicular carcinomas. All tumour 
stages were classified according to fifth edition of AJCC (Fleming et al., 1997) since most 
studies reported having used this classification. In the present study all papillary 
carcinomas of the thyroid <1 cm in diameter were classified as MPTC (Hedinger et al., 1988). 
All thyroid cancer cases were also characterized by sex, date of birth, and date of diagnosis. 
We also recorded data on number of thyroidectomies recorded in the registry which were 
almost exclusively performed by two senior surgeons during the study period. Near-total 
thyroidectomy has been used as standard treatment protocol for thyroid cancer and 
comprises neck dissection if confirmed lymph node involvement; one course of ablative 
radioiodine treatment with 100 mC, further radioiodine therapies with 100 mC if needed, 
with an interval of 6 months-1 year and thyrotropin-suppressive thyroid hormone therapy 
with levothyroxine lifetime.  
2.2 Follow up the vital status of patients 
Active follow-up of patients was carried-out through searches in medical records and phone 
contacts. A detailed review of the medical record to ascertain the cause of death was made. 
Mortality data were taken into account only when primary cause of death was directly 
related to thyroid cancer and all other deaths were considered censorings. Cause-specific 1-, 
5-, 10-, 20- and 25 year survival rates were used as measures of survival.  
2.3 Study population 
The studied population had an average of 500,000 inhabitants. Corresponding population 
data by size, age, sex, and year were available from official statistics. Data during the period 
1978–2001 show that Vigo’s population increased by 6.3%. The male to female ratio 
remained stable at about 0.92. The people of the region are homogeneous in terms of 
ethnicity. For studies of genetic characteristics, the Spanish Galician region is considered a 
relatively isolated European population at the westernmost continental edge (Salas et al., 
1998). 
2.4 Statistical analysis 
Trends in age, sex, histological type, and tumour size (differentiated thyroid carcinoma) at 
diagnosis were analyzed. Data on number of thyroidectomies performed were also recorded. 
The general descriptive analyses were performed using Microsoft Excel and SPSS 
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12.0 software (SPSS, Inc., Chicago, IL). Data were analyzed using the chi-square test for 
nonparametric data. A p value below 0.05 was considered to be statistically significant. 
Results were expressed as mean± standard deviation of the mean (mean±SD) for 
quantitative variables. Data were analyzed using the Student t test for normally distributed 
variables and the chi-square test for nonparametric data. Crude incidence rates, expressed 
per 100,000 inhabitants each year were calculated. In order to compare incidence rates 
between populations that differ with respect to age (since age has such a powerful influence 
on the risk of cancer), age standardized incidence rates were also calculated; standardization 
was performed using the World Standard Population (direct method) (Bray, 2002). For the 
whole group of thyroid cancer, the overall incidence by sex for each year from 1978 to 2001 
was calculated. Due to the small sample size, which produces unstable rates for individual 
years, rates were calculated for several years combined (1978 to 1985, 1986 to 1993, and 1994 
to 2001). Incidence trends for each of the distinct histological categories, including MPTC 
incidence, were also examined. The prevalence of thyroid cancer was defined as the number 
of persons in our defined population whom have been diagnosed of thyroid cancer, and 
who were still alive in three cross-sectional surveys performed in December 1985, December 
1993, and December 2001. The prevalence rates have been reported per 100,000 inhabitants. 
A 95% confidence interval (CI) for the rates was determined to compare incidence and 
prevalence rates. Survival from the data of initial surgery to each endpoint, i.e. cancer 
specific survival, was estimated by the Kaplan–Meier product-limit method at 1, 5, 10, and 
20 and, in some cases, at 25 years of diagnosis. The log-rank test was used to assess 
difference between subgroups. Age at diagnosis was grouped into the same five categories 
used by previous EUROCARE studies: 15-44, 45-54, 55-64, 65-74 and 75-99 years. We used 
multivariate Cox analysis to calculate those independent variables related to the survival of 
differentiated thyroid cancer. 
3. Results 
A total of 322 cases of primary differentiated thyroid cancer were diagnosed in our area 
between 1978 and 2001. The mean age at diagnosis was 46.6 years (range, 8–91 years). Eight 
patients were younger than 18 years at diagnosis. The female to male ratio was 3.6/1.  
3.1 General characteristics on thyroid cancer 
3.1.1 Histological distribution 
Out of 322 cases of primary thyroid cancer, papillary was the predominant tumour type 
with 245 cases (76%), followed by follicular with 44 cases (13.7%), medullary with 23 cases 
(7.1%), and anaplastic with 10 cases (3.1%), (Table 1). The papillary to follicular ratio in the 
entire period was as high as 5.8; when MPTC cases were excluded, this ratio was 2. 
3.1.2 Age and sex distribution 
The youngest age at presentation corresponded to medullary and papillary cancers of the 
thyroid. Anaplastic cancer and Hürthle cells occurred at older ages. Of the total of thyroid 
cancers, 78.3% of the cases were females and 21.7% outstanding men. This female 
predominance is maintained in all histologic types (Table 4). 
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3.1.3 Pathologic Tumor-Node-Metastases (pTNM) distribution 
Altogether, 73% of the primary tumours presented with T1 to T3 tumor size; 15 % were 
locally invasive to extrathyroidal soft tissues (T4), 22% had metastatic involvement of 
cervical lymph nodes and 4.7% had distant metastases. Of 11.8% of cases the tumor size 
was unknown. Among all tumors, medullary and papillary carcinomas were the most 
commonly presented with cervical lymphadenopathy while follicular carcinoma the most 
often presented distant metastasis (Table 4). In our series, we identified 95 MPTC out of a 
total of 245 papillary thyroid cancers (38.7%). Of these, 87 cases (91%) were incidentally 
diagnosed in thyroidectomies performed for thyroid pathologies other than thyroid 
cancer. 
 
 Papillary Follicular Hürthle Medullary Anaplastic Total 
Nº cases 
(%) 
245 
(76%) 
32 
(10%) 
12 
(3.7%) 
23 
(7.1%) 
10 
(3.1 %) 
322 
 
Mean age 
(range) 
44 
(8-91) 
50 
(23-78) 
61 
(33-91)
43.8 
(19-78) 
71 
(52-89) 
46.6 
(8-91) 
Female/Male 4 3.5 5 2.28 1.5 3.6 
T1-T3 80 % 56 % 78 % 52 % 0 % 73 % 
T4 10.6 % 22 % 8 % 17.4 % 100 % 15 % 
N1 23 % 12.5 % 8 % 39 % 20 % 22 % 
M1 2.4 % 19 % 0 % 13 % 0 % 4.7 % 
Table 4. Thyroid cancer characteristics at diagnosis (1978-2001). 
3.1.4 Distribution of pTNM stages of thyroid cancer at diagnosis (1978-2001) 
Most of thyroid cancer patients (75 %) presented low pathological tumor-node,-metastases 
(stages I and II). Most papillary cancers presented with either stage I (63 %) or stage II (18 
%). Stage III accounted for fewer than 12 % of cases. Few (1.2 %) patients presented with 
distant metastases and had stage IV disease. For follicular and Hürthle cancers these figures 
were 37, 28, 15, 6% and 25, 58, 8 and 0 % respectively. Most patients with medullary thyroid 
cancer (43.5 %)  had stage II; patients with stage I accounted for only 4 %; and stages III and 
IV, 26 % and 13 % respectively. Figure 1, illustrates the distribution of pTNM stage and 
histologic subgroup of thyroid cancer patients. 
3.1.5 Trends in thyroid cancer presentation: Tumour size 
Table 1 shows no significant change over time for sex distribution and age between the three 
time periods (1978–1985, 1986–1993, and 1994–2001). The proportion of MPTC among total 
papillary thyroid cancers cases increased significantly over time: 16.7% (1978 to 1985), 23% 
(1986 to 1993), and 43% (1994 to 2001). The papillary to follicular ratio significantly increased 
over time from 2.3 to 3.6 and 11.5. When MPTC was excluded, the papillary to follicular 
ratios were 1.9, 2.7, and 6.6, respectively. Besides MPTC cases, no significant variations were 
observed with respect to tumour size (pT) at presentation, in papillary and follicular over 
time. For some patients there was no precise pathological description about tumour size 
(pTx), (Table 5).  
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Fig. 1. Thyroid cancer pTNM stages and histologic distribution at diagnosis (1978-2001). 
 
 1º Period 
1978-1985 
2ºPeriod 
1986-1993 
3ºPeriod 
1994-2001 
p 
Female/Male  4.3 3.6 3.4 0.854 
Mean age  ± DT (years) 42.2±16.5 46.8±17.2 47.6±16.7 0.601(1º vs·3º) 
Papillary/Follicular  2.3 3.6 11.5 0.000* 
Papillary (no-MPTC)/Follicular 1.9 2.7 6.6 0.013* 
  (%) MPTC/ Total Papillary  16.7 % 23 % 43 % 0.010* 
Papillary  
(no- MPTC) 
T2 (n=81) 47.8 % 45.8 % 60 %  
0.360 T3(n=20) 8.7 % 20.8 % 10 % 
T4(n=27) 17.4 % 18.8 % 17.5 % 
Tx (n=22) 26.1 % 14.6 % 12.5 % 
Follicular T1 (n=4) 7.7 % 16.7 % 0 %  
0.213 T2 (n=20) 38.5% 38.9% 61.5 % 
T3 (n=4) 0 % 11.1 % 15.4 % 
T4 (n=8) 15.4 % 16.7 % 23.1 % 
Tx (n=8) 38.5 % 16.7 % 0 % 
Table 5. Time trend of thyroid cancer presentation (1978-2001). 
3.2 Trends in thyroid surgery 
A total of 2345 thyroidectomies were performed during the studied period. During this 
period the percentage of the population undergoing a thyroid surgery significantly 
increased from 13.76 per 100,000 each year (95% CI 12.35–14.56) to 23.83 (95% CI 22.17–
I
II
III
IV
Unknown
Stage
100,00%
ANAPLASTIC FOLLICULAR HÜRTHLE
MEDULLARY PAPILLARY
37,50%
28,13%6,25%
15,63%
12,50% 25,00%
58,33%
8,33%
8,33%
4,35%
43,48%
26,09%
13,04%
13,04%
63,27%
18,37%
11,84%
1,22% 5,31%
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24.73) and 45.01 (95% CI 42.45–46.39) in 1978–1985, 1986–1993, and 1994–2001, respectively. 
The proportion of thyroid carcinomas among operated patients rose from 9.92% in 1978–
1985 to 12.31% in 1986–1993 and to 15.35% in 1994–2001, respectively (p <0.015). Total 
thyroidectomy accounted for 48% of initial surgical procedures (1978–1985) and 74% during 
1994–2001. 
3.3 Trends in thyroid cancer incidence 
As shown in Fig. 2 and Table 6, incidence rates were considerably lower for males than for 
females. Overall crude incidence of thyroid cancer in women increased significantly from 
1.61 per 100,000 each year (1978 to 1985) to 4.43 (1986 to 1993) and 10.29 (1994 to 2001). These 
figures in men were 0.35, 1.31, and 3.24, respectively. Age-standardized incidence rates 
(ASR) over this period show the same tendency, with a significant increase in females: 1.56 
per 100,000 each year (1978 to 1985) to 3.83 (1986 to 1993) and 8.23 (1994 to 2001); and males: 
0.33, 1.19, and 2.65, respectively (Table 6). 
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Fig. 2. Annual crude incidence of thyroid cancer, by sex (1978-2001); females (circles) and 
males (squares). 
 
 Females Males 
Period (years) 
Crude 
Incidence 
ASR * IC (95 %) 
Crude 
Incidence 
ASR * IC (95 %) 
1978-1985 1.61 1.56 1.03-2.08 0.35 0.33 0.08-0.58 
1986-1993 4.43 3.83 2.93-4.71 1.31 1.19 0.67-1.70 
1994-2001 10.29 8.23 6.82-9.63 3.24 .65 1.82-3.46 
Table 6. Time trend of crude and age-standardized incidence rates of thyroid cancer, by sex. 
(*) Age-standardized incidence rate (ASR). 
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3.3.1 Trends in thyroid cancer incidence by histopathology: Incidence of MPTC 
Figure 3 displays the overall (males and females) crude incidence rates of thyroid cancer in 
relation to the histological types; the increase in the incidence of thyroid cancer over the 
three periods of time was primarily due to an increase in papillary cancer incidence. After 
the second period, the incidence of follicular cancer decreased and there was no significant 
change in the incidence of MTC and anaplastic cancer. Table 7 shows that the increase in the 
incidence of PTC was the result of an increased incidence of both MPTC and papillary 
measuring more than 1 cm (Papillary non-MPTC). This occurred both in males and females. 
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Fig. 3. Time trend of crude incidence rates of thyroid cancer, by histology. 
 
 Females Males 
Period Papillary
No-
MPTC 
Incidence
 
CI (95%) 
MPTC 
Incidence
 
CI (95%) 
Papillary
No-
MPTC 
Incidence
 
CI (95%) 
 
MPTC 
Incidence 
 
CI 
(95%) 
1978-
1985 
0.97 0.55-1.38 0.14 -0.02-0.29 0.15 -0.02-0.32 0.10 -0.04-
0.24 
1986-
1993 
2.19 1.49-2.88 0.81 0.38-1.23 0.75 0.32-1.17 0.12 -0.05-
0.30 
1994-
2001 
4.82 3.65-5.98 3.94 2.89-4.99 1.58 0.89-2.27 0.79 0.30-
1.28 
Table 7. Time trend of papillary thyroid cancer crude incidence rates, by sex  
(CI: Confidence Interval) 
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3.4 Trends in thyroid cancer prevalence 
Table 8 shows that prevalence of thyroid cancer increased substantially between 1985 and 
2001 in both sexes. Thyroid cancer was significantly more prevalent in female than in male 
subjects. 
 
Year Sex Prevalence CI (95%) 
1985 Female 12.53 8.38-16.68 
1993 Female 65.89 53.23-78.56 
2001 Female 128.34 111.75-144.92
1985 Male 2.72 0.70-4.73 
1993 Male 17.85 10.99-24.71 
2001 Male 35.66 26.56-44.77 
Table 8. Time trend of thyroid cancer prevalence, by sex. 
3.5 Thyroid cancer survival 
We followed a total of 321 cases of thyroid cancer. The median follow-up was 7.7 years, 
ranging between 4 and 27.8 years. We recorded a total of 43 deaths, of which 30 (70%) were 
directly related to thyroid cancer, yielding a cancer- specific mortality rate of 9. 3 % for the 
whole cohort. Over 4 %( 4.3) of cancer -specific deaths was represented by patients with 
differentiated thyroid carcinomas. Among the remaining 13 deaths not attributable to thyroid 
cancer, 9 (69%) were due to second malignancies (three breast cancer case, 1 prostate cancer 
case, 1 case of sigmoid colon cancer, 1 case of liver cancer, 1 case of glioblastoma multiform, 1 
case of pancreatic cancer , 1 case of multiple myeloma) and 4 (31%) were attributed  to other 
causes. Overall survival of patients diagnosed with thyroid cancer in the period 1978-2001 was 
88 % at 25 years, being 90 % for women and 80% for men;  although survival was higher in 
women, there were no significant differences between both genders (p = 0, 097), (Table 9). 
When excluding MPTC, we observed a decrease in thyroid cancer survival. Thus, the overall 
survival of thyroid cancer was 84% at 25 years,  being 87% in women and 76% in men, again 
without significant differences between genders (p = 0.15), (Table 10). 
 
Gender Patients Survival 
  1 year 5  years 10  years 20 years 25  years 
Female 251 97% 93% 91% 90% 90% 
Male 75 95% 91% 84% 80% 80% 
Total 321 96% 93% 89% 88% 88% 
Table 9. Overall cause-specific survival of thyroid cancer (1978-2001). 
 
Gender Patients Survival 
 1 year 5 years 10 years 20 years 25 years 
Female 180 96% 91% 89% 87% 87% 
Male 56 94% 89% 81% 76% 76% 
Total 236 95% 90% 86% 84% 84% 
Table 10. Overall cause-specific survival of thyroid cancer (1978-2001), excluding MPTC. 
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3.5.1 Cause –specific survival according to age 
Table 11 and Figure 4, reflect the cause-specific survival by age group (excluding MPTC) 
and emphasizes the influence of age on the prognosis of patients with thyroid carcinoma. As 
can be seen there is one more striking decline in survival after 55 years of age.  
 
Age Patients Survival 
 1 year 5 years 10 years 20 years 25 years 
ago-44 117 100% 98% 96% 94% 94% 
45-54 45 97% 95% 95% 95% 95% 
55-64 34 90% 84% 74% 63% - 
65-74 22 86% 77% 69% 57%,18 years - 
75-91 18 83% 59% 47% 47%,18 years - 
Table 11. Cause-specific survival of thyroid cancer by age group, excluding MPTC (1978-2001).  
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Fig. 4. Cause-specific survival of thyroid cancer by age group, excluding MPTC (1978-2001).  
3.5.2 Cause -specific survival according to histological type 
As known, histologic type is a strong determinant of thyroid cancer survival. In our series, 
papillary thyroid cancer patients had 25-year specific-survival greater than 93 %, even when 
excluding MPTC. The survival of MPTC was 100% at 25 years in the present study. 
Follicular and medullary carcinoma patients had lower survivals (83% at 25 years and %at 
20 years, respectively). However, the prognosis was is ominous for anaplastic thyroid 
carcinoma (Table 12 and Figure 5). 
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Fig. 5. Cause–specific survival of thyroid cancer according to histological type (1978-2001). 
 
Histologic 
type 
Patients Survival 
 1 year 5 years 10 years 20 years 25 years 
Papillary 
(total) 
245 99% 97% 96% 95% 95% 
Papilar  
(no MPTC) 
160 98% 96% 95% 93% 93% 
Follicular  
(including 
Hürthle) 
43 97% 90% 87% 83% 83% 
Medullary 23 95% 86% 70% 63% - 
Anaplastic 10 40% 10% - - - 
Table 12. Cause-specific survival of thyroid cancer according to histological type (1978-2001). 
3.5.3 Cause –specific survival according to p TNM stage distribution 
Stage at diagnosis is a strong prognostic factor for thyroid cancer survival. Thus, cause 
specific-survival vas 100% at 25 years of follow- up in stage I. At more advanced stages 
survival decreases progressively (Table 13). 
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Stage Patients Survival 
  1 year 5 years 10 years 20 years 25 years 
I 171 100% 100% 100% 100% 100% 
II 71 100% 100% 97% 94% - 
III 38 97% 88% 69% 69% 69% 
IV 21 37% 15% 15% 0% - 
Unknown 20 100% 100% 94% 94% 94% 
Table 13. Cause-specific survival of thyroid cancer by pTNM stage (1978-2001). 
3.5.4 Prognostic analysis in differentiated thyroid carcinoma 
Risk factors associated with differentiated thyroid cancer mortality were identified by Cox 
regression analysis. Univariate and multivariate analysis results for thyroid cancer mortality 
are illustrated in Table 14. In the univariate analysis, the following factors were significantly 
associated with mortality for differentiated thyroid cancer: age, follicular histology, local 
tumor extension and distant metastases at presentation. Neither sex nor the presence of 
lymph node metastases contributed to mortality risk. Multivariate analysis confirmed as 
independent predictor variables of increased risk of cancer mortality-only age and presence 
of distant metastases. 
 
Variables Variables 
Univariate 
Analysis 
Multivariate 
Analysis. 
RR (CI 95 %) RR (CI 95 %) 
Sex Female 1 
 
 Male 1,5 (0,48-4,95) 
 8 – 44 1  
 45 – 54 2,3 (0,14-36,7) 3,17 ( 0,2-51,6) 
Age (years) 55 – 64 20,7 (2,42-178) 17,8 (2,12-150) 
 65 – 74 30,5 (3,4-274) 15,6 (1,6-147) 
 > 75 38,5 (3,90-377) 38,5 (3,30-338) 
Histology Papillary 1 
 
 Follicular 4,07 (1,41-11,76) 
 T1 1 
 
Tumoral size T2 2,75 (0,26-24,5) 
 T3 3,33 (0,20-53,5) 
 T4 24,80 (3,1-198) 
Regional extension N0 1  
 N1 2,5 (0,78-8,40)  
Distance extension. M0 1  
 M1 29,9 (10,4-85) 17,68 (6,11-51,1) 
Table 14. Univariate and Multivariate survival analysis of prognostic factors of 
differentiated thyroid cancer (1978-2001). 
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4. Discussion 
The main objective of epidemiological studies is to measure the frequency of disease. 
Prevalence measures are particularly useful in the healthcare planning. Furthermore, 
incidence reflects the “flow” from health to illness in populations and therefore constitutes 
the basis of causative research. On the other hand, survival measures are an indicator of the 
global efficiency of healthcare services. These questions are also fundamentally important in 
thyroid cancer, since an understanding of the basic causes and related risk factors may lead 
to novel interventions and preventive measures. The reason why we carried out this work 
was the paucity of data on the major epidemiological features of thyroid cancer in our 
country (Spain) and particularly in our region (Galicia). In this study we conducted an 
epidemiologic survey in our community, to evaluate time trends in presentation, incidence, 
prevalence and survival of thyroid cancer between January 1978 and December 2001; a 
period that spans our community transition from mild iodine deficiency to iodine 
sufficiency after beginning iodine prophylaxis (iodized salt) in 1985. Several factors could 
have an impact on the epidemiology of thyroid cancer in our area. On the one hand, the 
eradication of iodine deficiency in our population in the last decades (Garcia-Mayor et al., 
1999; Rego-Iraeta et al., 2007; Rodriguez I et al., 2002), on the other hand, the progressive 
increase in the use of diagnostic techniques and the preference for carrying out near-total 
thyroidectomy since the nineties, (compared to the "lumpectomy" or hemithyroidectomy) 
which is known to increase the likelihood of detecting microscopic carcinomas incidentally, 
mainly papillary lineage. In Galicia, like in the rest of Spain, 97% of the population receives 
health care through the public health system, with other kinds of medical care being 
negligible (Etxabe & Vazquez, 1994). This ensures virtually complete case ascertainment for 
diagnosed thyroid cancer in the population. Given that practically the whole population of 
Galicia is registered with the social security system, our study is representative of the 
Galician population (North-western Spain).  
The general characteristics of our patients with thyroid cancer such as the mean age at 
diagnosis (46.6 years old) and the predominance of females to males (3.6/1) were similar to 
those reported in other studies around the world (Blanco Carrera et al., 2005; Gilliland et al., 
1997; Sant et al. 2003; Scheiden et al., 2006; Sciuto et al., 2009). Agree with this, the youngest 
age at presentation corresponded to medullary and papillary thyroid carcinomas, followed 
by follicular carcinoma, Hürthle cell cancer and finally by the anaplastic carcinoma. The 
histological distribution of thyroid cancer in the present series was similar to that reported 
in iodine-sufficient areas, with a higher proportion of papillary thyroid cancer (76% over 
overall thyroid carcinomas). It represents the same pattern that was reported in the USA 
(Hundahl et al., 1998; Scheiden et al., 2006; Schlumberger et al., 2008) and some European 
countries (Blanco Carrera et al., 2005; Farahati et al., 2004; Sant et al. 2003; Scheiden et al., 
2006). Likewise, in our series the ratio papillary/follicular was high, which is the 
predominant pattern reported in the Western world (Sant et al., 2003; Teppo & Hakulinen, 
1998). This happened even in the first period of our study when there was a mild iodine 
deficiency in our population (median iodine of 60μg/l) (Garcia-Mayor et al., 1999). This 
ratio increased over time, even when MPTC were excluded from the calculation. We 
speculate that the amelioration of iodine nutrition, which happened in our population over 
the last decades (Garcia-Mayor et al., 1999; Rego-Iraeta et al., 2007), may explain this finding 
to some degree. However, an increase in the incidence of papillary thyroid cancer has also 
www.intechopen.com
An Epidemiological Analysis of Thyroid Cancer in a  
Spanish Population: Presentation, Incidence and Survival 
 
19 
been reported in Luxemburg, considered an iodine deficient area (Sant et al., 2003), and in 
Tasmania (Australia), in spite of the recurrence of mild iodine deficiency (Burgess et al., 
2000). This phenomenon may be related with a dose-threshold effect for iodine nutrition and 
modulation of tumour genesis (Burgess et al., 2000), or alternatively, environmental factors 
other than iodine nutrition may be contributing.  
In our study, most of patients (75 %) had low pathological p-TNM stages (stages I and II) at 
presentation. These results are similar to those described in a cohort of more than 2700 
patients with thyroid cancer at the Mayo Clinic of Rochester who underwent thyroidectomy 
from 1940 to 1997 (Schlumberger et al., 2008). Among papillary carcinoma cases, this series 
reported extrathyroidal invasion in 15 % (range 5 to 34%), and clinically evident 
lymphadenopathy at presentation in about one third of cases. Only 1 to 7% of papillary 
carcinomas had metastases at diagnosis. However, it is noteworthy that about 35 to 50 % of 
removed neck nodes have histologic evidence of involvement (Schlumberger et al., 2008), so 
that our low rate of lymph node involvement may reflect the fact that node dissection is not 
performed routinely in our environment.  Regional lymph node metastases from follicular 
carcinomas are uncommon (4 to 6% of patients). Indeed, wherever they are observed, other 
alternative diagnoses, should be considered. Around 5 to 20% of these tumors have distant 
metastases at presentation (Schlumberger et al., 2008). In our series, 12.5% of follicular 
carcinomas and 8% of Hürthle cell carcinomas had lymph nodes at diagnosis. In accordance 
with previous observations, we found distant metastases in 19% of follicular carcinomas, 
although we found no distant metastases in the group of the Hürthle cell carcinomas. In 
relation to staging at presentation, we compared our results with the case material of the 
Mayo Clinic, between 1940 and 1997.  
The distribution of pathological stages I, II, III and IV for papillary carcinoma at the Mayo 
Clinic was respectively 60, 22, 17 and 1%, very similar to the corresponding in our study, 
which was 63, 18, 12 and 1.2% for the same stages. With regard to follicular carcinomas, the 
Mayo Clinic study found that the distribution of stages I, II, III and IV was 22, 53, 4 and 17% 
for follicular carcinoma and 17, 69, 9 and 5% for the Hürthle cell carcinoma. Curiously, stage 
I was more frequent among our follicular carcinomas (the distribution of stages I, II, III and 
IV for follicular carcinoma was 37, 28, 6.2 and 15.6% and for Hürthle carcinoma 25, 58, 8 and 
0%; respectively). With reference to medullary carcinoma, the Mayo Clinic cohort data 
revealed a predominance of stage I (stage I, II, III and IV; 57, 19, 22 and 2% respectively), 
while in our study only 4.3 % of patients presented with stage I. This is probably due to 
earlier introduction of RET proto-oncogene testing at the Mayo Clinic.  
Thyroid cancer has increased dramatically in most countries in the last 30 years (Kilfoy et al., 
2009), excluding countries such as Iceland, Sweden and Norway (Engholm et al., 2009). In 
the present study, the incidence of thyroid cancer is increasing over time. When comparing 
incidence rates among different populations there are two points to bear in mind; first, since 
a rapid increase in thyroid cancer incidence is seen, it is important to consider the period of 
time the rate refers to, and secondly due to the differences in the age distribution among 
different populations, it is necessary to display an age-standardized rate of incidence (ASR). 
Most of the series, report ASR referred to world population. In the present investigation, 
both crude incidences and ASR show an increasing trend over time. In comparison  
with other European countries, our ASR in the final period of time, 1994-2001, (8.2 per  
100,000-year in women  and 2.65 in men) is similar to the reports from our 
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neighbouring countries such as Portugal, France and Italy and is higher than that reported 
by the IARC for Spain (period 1997- 1999) (Ferlay et al., 2004). A previous study in our 
community (Garcia-Mayor et al., 1997), reported a decrease in the number of patients 
requiring surgical treatment with an increase in the frequency of malignancy in the surgical 
specimens after the introduction of FNAB in the management of nodular thyroid disease in 
1991. However, when we studied the total number of thyroid surgeries performed in our 
population, we found that the rate of population undergoing thyroid surgery significatively 
increased over time with an increase in the ratio of total thyroidectomy for other kind of 
thyroidectomy. Undeniable, this trend makes it easier to detect MPTC. In fact, 43 % of our 
operated cancers were MPTCs in the latter period studied versus a 16.7 % in the first period. 
A similar trend has been reported in France where there was an increase in thyroid cancer 
incidence, mainly due to the papillary type, with an epidemic of microcarcinomas (43% of 
operated cancers, for the period 1998–2001) (Leenhardt et al., 2004a). This trend has been 
reported in many other studies (Chow et al., 2003; Colonna et al., 2007; Scheiden et al., 2006; 
Verkooijen et al., 2003). The improvement in diagnostic tools (image procedures and fine-
needle aspiration biopsy) (Colonna et al., 2007; Scheiden et al., 2006) and greater 
extensiveness and  number of thyroidectomies performed, which makes it easier to detect 
MPTCs (Leenhardt et al., 2004a), has been suspected to be of etiological importance in the 
observed increase of papillary thyroid cancer. One study (Kovacs et al., 2005) estimated the 
prevalence of thyroid microcarcinomas found at autopsies is 100–1000 times higher than in 
clinical cancer; they were not related to iodine intake and were exclusively of the papillary 
type (MPTC). It suggests that a large proportion of the population probably lives with 
undetected thyroid cancer and fits with the hypothesis of an apparent increase in thyroid 
cancer incidence. Any interpretation of reports of the incidence of papillary thyroid 
carcinoma must take into account the remarkably high prevalence of MPTC in thyroids 
removed for reasons other than thyroid cancer and in autopsy series (Hedinger & Sobin 
1988). In this sense, it is noteworthy, that many cancer registries do not specify the 
contribution of MPTC to the incidence of thyroid cancer, so differences in the inclusion 
criteria can cause mistakes in the comparison of the incidences (Teppo & Hakulinen 1998). 
For these reasons we have separately analyzed the incidence of MPTC and the incidence of 
papillary cancer not including MPTC (Papillary non MPTC). In the present investigation, we 
found 245 cases of papillary cancer, of which 95 cases (38.7 %) were MPTC carcinomas 
(pT1). Remarkably, most of these tumours (91%) were detected incidentally after thyroid 
surgery performed for reasons other than thyroid cancer. Although the incidence of MPTC 
is increasing in our population, also an increase in the incidence of tumours greater than 1 
cm (Papillary non MPTC) was evident in both sexes. Similar findings have been reported in 
studies performed by Burgess in Australia (Burgess, 2002; Burgess & Tucker 2006). We also 
observed an increase in the ratio of total thyroidectomy for other kind of thyroidectomy 
over time. A recent study performed by Mitchell et al. in USA (Mitchell et al., 2007), 
examined trends in surgical therapy for thyroid cancer. They hypothesized that if a true 
increase occurs in the incidence of thyroid cancer, then thyroidectomy, as the primary 
treatment for thyroid cancer, should also increase during the same period. This study 
reported a regional difference in the incidence of thyroid cancer with an increase in North-
eastern and Southern and an actual decrease in the Midwest United States. Newly papillary 
thyroid cancer accounted for most of this increase. Furthermore, thyroidectomy, in these 
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areas seemed to mirror their respective regional changes in incidence. Supporting the 
hypotheses of recent changes in medical practice as the cause of the increase in thyroid 
cancer incidence, some authors (Davies & Welch, 2006; Kent et al., 2007) found a shift in the 
tumour size distribution of thyroid cancer toward smaller papillary cancers in recent years, 
suggesting an apparent (not real) increase in thyroid cancer incidence due to increased 
detection of subclinical tumours. However, besides MPTC, we did not observe a significant 
change in tumour size over time in differentiated thyroid carcinomas at presentation with a 
percentage of pT2, pT3 and pT4 lesions which remain stable over time. Moreover, there are 
three questions to be in mind; firstly, the increase in thyroid cancer incidence in our area has 
happened equally in the incidence of MPTC and in the incidence of PTC greater than 1 cm.; 
secondly, there has not been a shift over time in thyroid cancer tumour size, besides MPTC, 
and thirdly, there is no similar increase in the incidence of other histological types of thyroid 
cancer (Rego-Iraeta et al., 2009). Interestingly, Kent and colleagues (Kent et  al., 2007) found 
that the incidence of medium-sized tumours (2-4 cm) remained stable over time, but were 
surprised to discover a slight increase in large tumours (larger than 4 cm). Several others 
papers from U.S. support the notion that the increase in incidence is not entirely due to 
increased screening and detection. Thus, Enewold and colleagues found, among white 
women, the rate of increase for cancers larger than 5 cm. almost equaled that for the smallest 
papillary cancers. Chen et al. similarly reported an increase in differentiated thyroid cancer 
of all sizes with the most rapid increase occurring in females. Cramer et al. showed an 
increase in the incidence of papillary thyroid cancers with a significant increase in all size 
categories. A report by Morris & Myssiorek drew similar conclusions based on data 
demonstrating significant rises in the incidence of large (>4 cm), and well-differentiated 
cancers with clinically significant pathological adverse features (Chen et al., 2009; Cramer et 
al., 2010; Enewold et al., 2009; Hodgson et al., 2004; Morris & Myssiorek, 2004). Improved 
detection has undoubtedly occurred and may explain much of the increase in small well-
differentiated cancers. However, the most important evidence that increased diagnostic 
activity is not the sole cause for this increase is that large and more advanced cancers are 
increasing as well as small tumours. This trend suggest than some environmental factor, 
besides increased diagnostic activity, may be contributing to the increase in thyroid cancer 
incidence. Thyroid cancer can be induced in experimental animals directly by mutagenic 
carcinogens and indirectly through hormone imbalance.  
The only well established risk factor for thyroid cancer in humans is ionizing radiation. Sex 
hormones, iodine deficiency and other factors (nutritional, volcanoes) have been proposed 
as risk factors for thyroid cancer, but the findings are inconsistent (Nagataki & Nystrom, 
2002). The increase in thyroid cancer risk could be attributed to ionizing radiation exposure. 
Studies of individuals living in the Chernobyl areas have shown an increased risk among 
those exposed as children (Cardis et al., 2006). In our study, only 8 cases of thyroid cancer in 
people of 18 years of age or less could be identified, so ionizing radiation exposure cannot 
explain the recent increase in incidence of thyroid cancer in our community. However, a 
longer latency period for low doses of radiation could not be ruled out (Yamashita, 2006). 
Some authors have suggested that iatrogenic exposure to radiation during imaging by 
computed tomography, especially in children when radiation sensitivity of the thyroid 
gland is greater, could contribute to the increase in thyroid cancer (Baker & Bhatti, 2006); 
however this link remains unproven at the moment. Nutritional factors such as a low fruit 
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and vegetable and selenium consumption have been linked to thyroid cancer and cancer in 
general (Clark et al., 1996; Franceschi et al, 1990; Rayman, 2000). The role of Brassica 
vegetable in cancer protection (Keck & Finley, 2004; Verhoeven et al., 1996) has also been 
reported. Remarkably, our soils are acidic with low selenium content and the consumption 
of these Brassica vegetables (cabbage), traditional in our community of the North-West of 
Spain, has decreased over the last decades due to the globalization of our diet and loss of the 
popularity of these foods because of their goitrogenous potential.  
Contrary to what happened with reports on the incidence of thyroid cancer, reports on 
prevalence are scarce. In the USA, the prevalence estimate for thyroid cancer was 310,000 in 
2001 (Sherman & Fagin 2005), averaging about 105 cases per 100,000 population. In our 
study, we observed an increase in the prevalence of thyroid cancer from 8 cases per 100,000 
population in 1985 to 83 cases in 2001. The prevalence varied for both sexes, with the figure 
being greater in women (128 cases per 100,000 in 2001). The increase in thyroid cancer 
incidence seen in our area together with the good prognosis of this neoplasia can explain the 
increase in the prevalence of thyroid cancer. These data should be taken into account when 
planning health resources for the management of these patients. 
In the present study, we also performed an analysis of cause–specific survival in our 
patients diagnosed of thyroid cancer between 1978-2001. In the case of deceased patients, we 
investigated the exact cause of death by reviewing the medical records to carry out the 
calculation of cause-specific survival. Throughout the follow-up period, we recorded in our 
series a total of 43 deaths, of which 70% were directly related to thyroid cancer. Among the 
remaining deaths not attributable to thyroid cancer, 69% were due to second malignancies. 
A high percentage of secondary neoplasms as the cause of death in thyroid cancer patients is 
also reflected in other series, for example, a Norwegian and a Dutch study found a 38% and 
58% of deaths, respectively, attributable to other malignancies (Akslen et al., 1991; Eustatia-
Rutten et al., 2006). In Europe we have data on thyroid cancer survival from the 
EUROCARE database. As the first publication on cancer survival in Europe, EUROCARE-1 
(1978-1985) (Berrino et al., 1995) did not involved thyroid cancer, EUROCARE-2 (1985-1989) 
(Teppo et al., 1998) was the first publication on thyroid cancer survival. We also have more 
recent data from the EUROCARE-3 (1990-1994) (Sant et al., 2003). Both studies were 
population-based and used relative survival, i.e. an estimate of excess mortality. Five-year 
relative survival collected for Spain in the EUROCARE-3 (85.7% women and 82% in men) 
places it slightly above the European average (81.4% females and 71.8% in men). In our 
study, we observed an overall thyroid cancer cause-specific survival after excluding MPTC 
(91% in women, 89% in men) that is better than those previously reported over European 
countries as was reflected in the EUROCARE 2 and 3. As expected, we observed that 
survival decreases gradually with age in our study. We found a 5-year survival of 65% in 
the group older than 75 years (59% when excluding the MPTC). With regard to the 
histologic distribution, cause-specific survival at 25 years in our series is 95% for papillary 
thyroid carcinoma (93% if we exclude MPTC) and 83% for follicular carcinoma (including 
Hürthle cell). In the case of medullary carcinoma, the 20-year survival rate was 63%. As 
expected, anaplastic carcinoma was an ominous prognosis with a 5-year survival rate of 
10%. We can compare these results with those of the cohort of patients with thyroid cancer 
at the Mayo Clinic (Schlumberger et al., 2008), where the cause-specific survival at 25 years 
for papillary thyroid carcinoma was 95%, wich was significantly higher than the rates found 
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for medullary, Hürthle and follicular thyroid carcinoma, wich were 79, 71 and 66%, 
respectively. Curiously, patients with medullary thyroid carcinoma at the Mayo Clinic have 
similar or better outcomes than those patients with non papillary follicular thyroid 
carcinoma; as more patients have been diagnosed by genetic testing, most of them have 
curable disease and better survival. With regard to survival by histologic type, we found 
very similar results to those published in the U.S. series  (Hundahl et al., 1998 ) where 10-
year overall relative survival rates for patients with papillary, follicular, Hürthle cell, 
medullary, and  undifferentiated/anaplastic carcinoma were 93, 85, 76, 75 and 14%, 
respectively (Hundahl et al., 1998). In our series, 10-year cause-specific survival for papillary 
thyroid carcinoma was 96% (95% if we exclude the MPTC, 87% for follicular carcinoma 
(including Hürthle cell), 70 % for medullary carcinoma and 0% for anaplastic carcinoma. A 
similar distribution of histologic types and pTNM stages may be one explanation for these 
similar results. With regard to staging, as expected, we found a survival of 100% at 25 years 
for tumors which were presented in stage I. Accordingly; we did not record any deaths due 
to thyroid cancer in our 95 cases of MPTC. Survival gradually worsened with more 
advanced staging at presentation, being only 15% at 10 years for stage IV tumors. In our 
study, the stage of tumors at presentation was generally favorable, which may have 
contributed positively to overall survival. Despite being a relatively benign disease, a 
continual decline in cancer-specific survival is noted in all tumor stages at successive follow-
up intervals. This underscores the need of life-long surveillance for thyroid cancer patients.  
Another objective of this study was to describe the prognostic factors associated with 
thyroid cancer survival. Because these variables are often strongly interrelated, we have 
identified risk factors associated with mortality from differentiated thyroid cancer using the 
Cox regression analysis. This was determined only in the group of differentiated thyroid 
carcinomas, as the rest of the tumors represent a little large in total thyroid cancers and they 
have a different clinical behavior. Age, follicular histotype, local tumor extension as well as 
distant metastases were found to have a significant negative influence on survival in the 
univariate analysis. However, in the multivariate analysis, only age and distant metastases 
were found to retain their independent prognostic values. Multiple studies have identified 
several prognostic factors, but overall the findings have been inconsistent, possibly due to 
bias introduced by the use of different institutional series with different distributions of 
histologic types and differences in follow-up and histologic classification of disease. 
Therefore, we do not know the relative importance of each of these features as prognostic 
factors and whether the findings  in one population can be generalized to other populations 
(Gilliland et al., 1997). Although the majority of studies reported the effect of age on the 
prognosis of patients with differentiated thyroid carcinoma, data from some studies (Elisei 
et al. 2010; Gilliland et al., 1997; Hundahl et al., 1998; Sciuto et al. 2009) also suggest an effect 
on other thyroid histologies as well. The association between age and survival is not 
explained by differences in stage at diagnosis, differentiation, socio-demographic variables, 
or treatment. It has been speculated that other age-dependent factors such as nutritional or 
immune status, or differences in the spectrum of genetic alterations in tumors in the elderly, 
may play a role in survival (Gilliland et al., 1997). In this sense, several studies have found 
that survival does not differ for patients of similar ages and stages diagnosed with papillary 
or follicular carcinoma (Thoresen et al. 1989; Torres et al., 1985). Children and people 
younger than 20 years tend to present with higher stage disease and greater likelihood of 
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locoregional and distant metastases, despite it, children generally have excellent survival 
rates, the exception to this rule is the disease in children aged < 10 years (Sipos & 
Mazzaferri, 2010). In the same line as most of the studies (Beenken et al., 2000; Eichhorn et 
al., 2003; Gilliland et al., 1997; Lerch et al., 1997; Mazzaferri, 1999; Shah et al., 1992), we 
found that the presence of distant metastases at presentation is an independent risk factor in 
the prognosis of differentiated thyroid carcinoma. The main cause of death from 
differentiated thyroid cancer is distant metastases (Mazzaferri, 1993). Mortality is high with 
distant disease, with 50 % survival at 3.5 years according to one recent study (Sampson et 
al., 2007). However, survival is improved in younger patients (Sampson et al., 2007), patients 
with microscopic rather than macroscopic disease (Durante et al. 2006), and patients with 
iodine-avid tumours (Durante et al. 2006; Sampson et al., 2007). Furthermore, the ability to 
achieve a negative post-treatment scan after multiple doses of radioiodine was associated 
with 92% overall 10-year survival, compared with 19% survival for patients who did not 
achieve a negative post-treatment scan (Durante  et al. 2006). Numerous factors affect 
outcome of patients with thyroid cancer; in spite of these various factors, only a few are 
considered in the currently recommended TNM staging system. The clinician must therefore 
have a complete understanding of the various prognostic factors and how they contribute to 
the outcome, so that the patient can be counselled accordingly about treatment and long-
term surveillance decisions (Sipos & Mazzaferri, 2010). 
5. Conclusions 
In conclusion, we have analyzed for the first time, the descriptive epidemiology of thyroid 
cancer in Vigo, Galicia (Spain), between 1985 and 2001. Long term follow-up ascertainment 
was practically complete, providing valid information on thyroid cancer prognosis. The 
results of this study can be summarized as follows: the first point to note is the histologic 
distribution of thyroid cancer in our population; wich is similar to that found in areas with 
high iodine intake, with a clear predominance of differentiated thyroid carcinoma and a 
high ratio of papillary to follicular carcinomas. As in many other regions and countries, the 
incidence of thyroid cancer is increasing and this trend is primarily caused by an increase in 
the incidence of papillary type. Our data showing an increase in papillary cancers larger 
than 1 cm suggest that some environmental factor may be contributing to this trend. There is 
a significant increase in the prevalence of thyroid cancer over time, especially among 
women. These data should be taken into account when planning health resources for 
management of this disease. Cause-specific survival of thyroid cancer in our study is higher 
than the European average, similar to that found in the U.S. series of thyroid cancer. 
Possible explanations for these results are: a high proportion of differentiated carcinoma, 
particularly papillary thyroid carcinoma, and a favorable stage (I and II) of the tumors at 
presentation. This study has some limitations: the relatively limited number of cases, 
particularly for selected histologic type; the study is merely descriptive, so it is not possible 
to give a definitive explanation for the observed increase in the incidence of thyroid cancer. 
His strength is also limited because we could not continue the study beyond 2001 in order to 
see if this trend continues or instead, the incidence of thyroid cancer reaches a plateau. 
Furthermore, information on a number of variables, such as vascular invasion, tumour 
recurrence and treatment (dose and frequency of I-131) were not controlled and may have 
influenced on survival. Further studies in these areas seem prudent. 
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